Bacillus subtilis HU58 and Reduced Blood Ammonia Levels

Doses used in studies

Safety in these studies

Overall tolerabilityReported
Daily treatment with oral B. subtilis HU58 was safe and well tolerated over a 4-week period in patients with hepatic encephalopathy
from: An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated
serious adverse eventsReportedSerious adverse event
One patient (9.1%) taking placebo and two (6.9%) taking the probiotic experienced serious TEAEs (SAEs); none resulted in study discontinuation and all were considered to have no/unlikely relationship to the study product.
from: An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated
treatment-emergent adverse eventsReported
Mild or moderate treatment-emergent adverse events (TEAEs) were reported in 27.3% and 17.2% of patients in the placebo and probiotic groups, respectively; no severe TEAEs were reported.
from: An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated

1 of 1 paper

An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy